PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Neoplasm Recurrence, Local”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 541 records · Page 30Linked to original sources
PubMed1989

[Repeated yearly BCG treatment in superficial bladder cancer].

The authors report on experiences of treatment for superficial bladder cancer with BCG have achieved during three years. To achieve a permanent recidive prophylaxis the 6 weeks long course was repeated yearly. During the 37-12 months follow up a tumor recurrence have been observed in 10 of 49 patients (20.4%). There have not been seen any serious side-effects requering the interruption of the course or requering any antituberculotica. On the basis of their results and the torelable side-effects they recommend the local BCG treatment as a favourable possibility in prevention of bladder tumor recurrence.

BCG Vaccine↗
PubMed1989

[Clinical results of thermoradiotherapy of locally advanced and recurrent breast cancers--comparison of results with radiotherapy alone].

From August 1979 through January 1988, 23 breast cancer patients with 25 tumors supposed to be refractory to conventional treatment were treated by thermoradiotherapy. Of the 25 tumors, 10 were locally advanced primary tumors [Group 1], 4 locally advanced recurrent tumors after operation more than 5 cm in maximum diameter [Group 2], and 11 locally recurrent tumors after radiotherapy [Group 3]. The present study was not a formal randomised-trial, but a historical-controlled study. The results were compared with tumors which were treated by radiation therapy alone between July 1962 and August 1979. The historical control groups comprised 11 tumors for Group 1, 17 for Group 2 and 19 for Group 3. Employing 4 types of heating devices (8, 13.56 MHz capacitive RF, 430, 2450 MHz microwave), hyperthermia was administered once or twice a week after irradiation, for 30-60 minutes per session, up to a total sessions of 2-9. Radiotherapy was delivered in fractions of 180 to 200 cGy per day, 5 days per week, up to 28-74.4 Gy in total, or in fraction of 400 cGy, two times per week, up to 28-60 Gy. Tumor temperatures were measured by inserting thermocouples into the tumors. The tumors that did not recur during follow-up of more than 3 months were regarded as locally controlled tumors, and the local control rate was calculated. The local control rate in Group 2 and the local response rate (CR + PRa) in Group 1 were higher than those of the historically controlled tumors. In Group 3, hyperthermia combined with lower total doses of irradiation showed a high local response rate similar to that by radiation therapy alone. Thus local hyperthermia in combination with radiation therapy seems to be more effective than radiotherapy alone for locally advanced and recurrent breast cancers.

Adult↗
PubMed1982

[Combined treatment of rectal cancer].

The comparative analysis of two methods of treatment (a combined method with the preoperative radiotherapy and a purely surgical one) of 363 patients with carcinoma of the rectum has shown that an intensive concentrated course of radiotherapy with irradiation of extended fields (the irradiation zone includes the small pelvis cavity and paraaortal lymph nodes up to the level of the second lumbar vertebra) is satisfactorily endured by the patients and does not complicate the operation. In the postoperative period the patients subjected to preoperative radiotherapy showed a longer healing of the perineal wound. The authors failed to reveal any difference in the results of a 3-year survival of the patients after the combined and purely surgical methods of treatment. Local recurrencies were found to be less frequent following the combined method.

Humans↗
PubMed1996

Late local recurrence after radiotherapy for tongue and early glottic carcinoma.

BACKGROUND/AIM: Late local recurrence after radiotherapy for tongue and early glottic carcinoma is rarely discussed. In the head and neck cancer, approximately 90% of local recurrence occurred within 2 years after radiotherapy. However, we found that late local recurrence after radiotherapy for glottic cancer was not rare. Our aim was to evaluate the late local recurrence after radiotherapy for early glottic and tongue cancer. PATIENTS AND METHODS: From 1967 through 1982, 633 patients with tongue carcinoma and 330 patients with early (T1T2N0) glottic carcinomas were treated at the Department of Radiology, Osaka University Hospital. Of these 821 patients, 329 patients with tongue carcinoma and 221 patients with early glottic carcinoma survived at 5 years after radiotherapy without local recurrence. For tongue carcinoma, patients were divided by T category. For early glottic carcinoma, patients were divided by the tumor response at 40 Gy. RESULTS: Late local recurrence occurred in 23 of 329 patients (7%) with tongue carcinoma, and in 9 of 221 (4%) with early glottic carcinoma. For tongue carcinoma, late recurrence occurred in 19 of 249 patients (8%) in stage I and II, and 4 of 80 patients (5%) in stage III and IV. For glottic carcinoma, late recurrence occurred in 8 of 137 patients (6%) with tumor clearance at 40 Gy and 1 of 63 patients (2%) with tumor persistence at 40 Gy. The incidence of double cancer was also evaluated. Of 329 5-year survivors with tongue carcinoma, 39 patients (12%) had another malignancy, and 26 patients of 221 5-year survivors with early glottic carcinoma (12%) had also another malignancy. Of 39 double primaries of tongue carcinoma, 10 patients (26%) had head and neck malignancies, and none of 26 double primaries of early glottic carcinoma. CONCLUSION: Late local recurrence was not rare in tongue and early glottic cancer. Poor prognostic group showed lower incidence of late recurrence than good prognostic group. This result suggests that secondary tumor at the same site of primary tumor is late local recurrence.

Carcinoma↗
PubMed2004

External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.

PURPOSE: To analyze the results of clinically node-negative, localized hormone-refractory prostate cancer treated with external beam radiotherapy (EBRT) and to investigate the potential prognostic factors that influenced the therapeutic outcome. METHODS AND MATERIALS: Fifty-three patients who had developed localized hormone-refractory prostate cancer were treated with EBRT between 1994 and 2001. According to the 1992 American Joint Committee on Cancer clinical stage, 4 patients had T2 and 49 had T3 at the start of RT, and 14 patients had a Gleason score <7, 14 had a Gleason score of 7, and 23 had a Gleason score of 8-10. All patients were treated with EBRT using the unblocked oblique four-field technique, with a total dose of 69 Gy. The fraction dose was 3 Gy three times weekly. The median follow-up after RT was 35 months (range, 8-96 months) and after androgen ablation was 73 months (range, 42-156 months). RESULTS: Of 53 patients, 15 patients subsequently developed clinical relapse, including locoregional and/or distant metastases. The site of first relapse was bone metastasis in 10, lymph nodes in 3, and local failure in 2 patients; 3 patients died of prostate cancer during the analysis period. The 3-year and 5-year cause-specific survival rate was 94% and 87%, respectively, and the 3-year and 5-year clinical relapse-free survival rate was 78% and 56%, respectively. The univariate analysis revealed that a short prostate-specific antigen (PSA) doubling time and high PSA value at the start of RT and a high Gleason score were statistically significant factors for the risk of clinical relapse. Multivariate analysis demonstrated that the PSA value (PSA or=15 ng/mL) at the start of RT was an independent prognostic factor. CONCLUSION: EBRT could be a treatment of choice for clinically node-negative, localized, hormone-refractory prostate cancer.

Aged↗
PubMed1998

Accuracy of computed tomography in determining resectability for locally advanced primary or recurrent colorectal cancers.

AIM: To determine the accuracy of computed axial tomography (CT) in determining tumor resectability in patients with locally advanced primary (T4) or locally recurrent colorectal cancer. METHODS: Computed tomography scans of 84 patients with "resectable" locally advanced primary rectal cancer (n = 12) or recurrent colorectal cancer (n = 72) were compared with the operative findings to assess the accuracy of abdominal and pelvic CT in determining extent of disease and resectability. RESULTS: At surgery, disease was confined to the pelvis in 63 patients, the abdomen in 7, and involved both the pelvis and abdomen in 14. Computed tomography correctly identified these anatomic sites of tumor in 87% of patients, with 89% and 80% accuracies for pelvic and abdominal disease, respectively. Tumor resection was performed in 71 patients (85%), but was not in 13 patients because of locally unresectable disease in 8 and metastatic disease in 5. The accuracy of predicting tumor-related operability was 85%. With regard to adjacent organ resection, CT was accurate in determining the need for sacrectomy or hysterectomy, but overestimated the need for urinary organ resection. Based on histological examination of resection margins, CT correctly staged (n = 45) or overstaged (n = 9) 54 patients (64%) and understaged the remaining 30. The ability of CT to preoperatively predict a locally advanced tumor after preoperative radiation therapy as not being fixed was 30%, fixed but resectable 75%, and fixed but not resectable 25%. CONCLUSIONS: Computed tomography is generally reliable at identifying disease as being confined to one region, and for predicting the need for adjacent organ resection. It is less discriminating for predicting local tumor resectability.

Adult↗
PubMed1990

Effect of doxorubicin on local recurrence following marginal resection in the MGH-OGS murine model.

Despite the fact that preoperative chemotherapy causes substantial necrosis in the primary osteosarcoma tumor, most authorities recommend resecting these lesions with a wide margin of normal tissue to avoid local recurrence. This study evaluated the effect of systemic chemotherapy (doxorubicin) on tumor growth and histology in the MGH-OGS transplantable murine model and examined whether this drug prevents local recurrence after resection of the tumor with positive microscopic margins. The results indicate that doxorubicin caused prolonged cessation of tumor growth, produced substantial necrosis within the lesion, and decreased the risk of local relapse following marginal surgery. The drug effect was dose-dependent and drug efficacy in preventing local relapse was maximal with administration prior to or at the time of surgery.

Animals↗
PubMed1998

Prognostic markers in clinically localized prostate cancer.

Current dilemmas for physicians managing patients with localized prostate cancer include deciding: (1) which patients need aggressive treatment; (2) what treatment options are best for a given patient; and (3) what treatment outcomes can be expected. This article reviews our ability to prognosticate outcome (including pathological stage and disease-free survival rate) in patients with clinically localized adenocarcinoma of the prostate (AJCC, stage T1-T2. N0, M0) subsequent to analysis of several contemporary series involving patients treated with radical prostatectomy and external-beam radiation therapy. Pretherapy prostate-specific antigen (PSA) level (< or =4 ng/mL or >20 ng/mL) and Gleason score (< or =4 or > or =8) as individual variables provide independent prognostic information for only a subset of patients undergoing radical prostatectomy and external-beam radiation therapy. Pathological stage is the most powerful predictor of outcome following radical prostatectomy, and its prediction (organ-confined vs. seminal vesicle or lymph node involvement) is aided by knowledge of clinical stage, Gleason score, and PSA level. Planned systematic biopsies also provide useful prognostic information for the prediction of pathological stage and tumor volume, as well as providing additional tissue for pathological assessment of tumor heterogeneity. Several novel markers of biological aggressiveness are associated with critical steps of the metastatic cascade (growth, invasion, angiogenesis, and resistance to apoptosis) and include the p53 tumor suppressor gene, the bcl-2 proto-oncogene, markers of increased proliferation (Ki-67), apoptosis, and angiogenesis (microvessel density). Their evaluation in clinical specimens is currently being used to prognosticate outcome. Current clinical and pathological parameters provide a "ballpark" estimate of outcome for patients with clinically localized prostate cancer. Further elucidation of the critical molecular events associated with prostate cancer progression and metastasis should help in identifying molecular markers that more accurately predict the prognosis for an individual patient with clinically localized prostate cancer.

Adenocarcinoma↗
PubMed1978

[Ultrasonic diagnostics in the scope of clarification and prognosis of oncologic cases (author's transl)].

By means of ultrasonic diagnosis it is possible to represent neoplasms in the abdomen, retroperitoneum and small pelvis. The real-time scanner is utilized in tumor localization and search for metastases, whereas an exact measurement of the tumor, possible of a representative metastasis, and also the treatment planning, are performed with the cross-sectional images from the storage compound scanner. Controls during cancer therapy will give information about the therapeutic results. Recurrences or newly spread metastases may easily be detected by this method in the course of follow-up of the tumor patients.

Abdominal Neoplasms↗
PubMed1977

Tumour regression as a guide to prognosis: a study with experimental animals.

An analysis has been made of the relationship between regression during therapy and the probability of local control in a group of mice treated with single doses and fractionated doses of X rays. The tumours were first generation transplants from spontaneous mammary carcinomas in C3H mice and were irradiated with single doses 3F/4 days, 9F/10 days, 9F/18 days or 15F/18 days. The size of the smallest radiation dose approached those encountered in clinical radiotherapy. A significant correlation was observed between the shrinkage during the treatment period and the local control at 150 days, for three of the four fractionated schedules. A weaker correlation was observed for shrinkage within a week after single doses, and for shrinkage during treatment with nine fractions in 18 days. It is postulated that the rate of shrinkage is an inherent characteristic of each individual tumour and does not reflect the number of cells killed. However, the shrinkage in some tumours during the course of therapy may result in more extensive reoxygenation which makes these tumours more sensitive to subsequent doses of fractionated course. The degree of shrinkage within the period of fractionated irradiation was found to be a useful prognostic guide to ultimate local control in individual tumours.

Animals↗
PubMed1980

Mayo Clinic experience with conjunctival melanomas.

One hundred twenty-six surgically excised pigmented lesions of the conjunctiva were evaluated and correlated with clinical data and follow-up information. Of these, 42 were classified as conjunctival melanomas, with 18 arising apparently de novo, 15 from acquired melanosis, and nine from nevi. The six tumor deaths occurred only in patients with melanomas arising de novo or from acquired melanosis, Patients with tumor deaths usually demonstrated local recurrences long before metastases occurred. Moreover, several patients had local recurrences treated repeatedly for years without metastatic spread. Recent clinical findings relating to skin melanomas were applied and evaluated.

Adult↗
PubMedDate not supplied

Multivariate analysis results of radiotherapy for laryngeal cancer.

We assess the impact of radiotherapy in the treatment of laryngeal cancer and evaluate the value of the standard dose (linear quadratic plus time model) and other variables to predict tumor control and survival. Between 1972 and 1989, 80 patients with laryngeal cancer received comprehensive radiotherapy. Patients with stage I laryngeal glottic cancer (T1-N0-M0) were excluded from this study. Mean follow-up was 15 months (range 4 to 181). The mean age was 64.8 years (range 40 to 92). Standard dose varied from 32.65 to 81.81 Gy (mean 66.78). The 5-year overall survival and tumor-specific survival rates were 44.9 +/- 5.8% and 51.4 +/- 5.9%, respectively. Five-year local control and locoregional control rates were 66.4 +/- 5.7% and 61.9 +/- 5.8%, respectively. Multivariate analysis showed that local control was significantly predicted by T stage (p = .032), but not by standard dose (p = .906). Independently significant factors predicting tumor-specific survival included stage (p = .006), site (p = .019), and age (p = .001). Local control and survival were significantly predicted by the TNM-staging classification. The standard dose did not predict local recurrence or survival.

Adult↗
PubMed1995

Collagen matrix cisplatin prevents local tumor growth after margin-positive resection.

The extent of a tumor, sometimes combined with its anatomic location, can compromise the surgeon's ability to obtain clear margins of resection. Regional recurrence of a tumor in the resection bed frequently produces significant local morbidity and limits patient survival time and quality of life. A positive margin resection model was created by induction of perinephric VX-2 tumors in New Zealand white rabbits followed by unilateral nephrectomy with grossly positive margins in the retroperitoneum. Resection bed injection of a novel collagen matrix with cisplatin (CDDP) and epinephrine prevented tumor recurrence in all treated animals. In contrast, control animals treated with CDDP alone, CDDP and epinephrine alone, or the collagen matrix with epinephrine had bulky tumor recurrence in the resection bed. Resection bed tissue levels of platinum were determined by flameless absorption spectrophotometry at 1, 4, and 7 days following nephrectomy and injection of the collagen matrix, CDDP, and epinephrine or CDDP and epinephrine without the collagen matrix. Significantly higher resection bed drug levels of platinum were achieved through the use of the novel collagen matrix than through the use of CDDP and epinephrine alone (P < 0.05). The results of this study indicate that tumor bed treatment with CDDP and a unique collagen matrix drug-delivery vehicle produces prolonged high resection bed levels of platinum and prevents local tumor recurrence.

Animals↗
PubMedDate not supplied

Male breast cancer: Austrian experience.

Data were collected on 169 men treated for breast cancer at 36 surgical departments in Austria between 1970 and 1991. We report here several of their clinical features and assess the importance of established prognostic factors. After a median observation period of 51 months 60 patients (35%) suffered a recurrence. The estimated 5-year recurrence-free survival for the entire group was 55%, and the estimated 5-year overall survival was 62%. Although stage-adjusted data are comparable to those for female breast cancer, the outcome in this series may be attributed to a relatively high frequency of advanced tumor stages. Tumor size (recurrence-free survival p = 0.00001; overall survival p = 0.03) and axillary lymph node status (recurrence-free survival p = 0.0001; overall survival p = 0.0001) proved to have a prognostic impact. Using a multivariate analysis, axillary lymph node status (recurrence-free survival p = 0.001; overall survival p = 0.01) still had prognostic influence. The various procedures used had no effect on local recurrence.

Adult↗
PubMed1993

Pattern of recurrence in rectal carcinoma: implications for the design of (future) studies on adjuvant therapy.

255 patients who underwent potentially curative surgical treatment for rectal carcinoma at the Cantonal Hospital Aarau from 1981 to 1989 have been followed up and the results analysed for overall survival and the timing and occurrence of local and distant recurrence in relation to the initial tumor stage. The patients had received standard surgical treatment for rectal carcinoma with the exception of 28 patients who had been randomized to the treatment arm of SAKK protocol 40/81 and were given perioperative adjuvant portal chemotherapy. 10 patients with large fixed tumors had preoperative radiation therapy. In UICC stage I most patients were cured by surgery alone, local recurrence as rare, and distant metastases appear in about 10% of pT2. cases. In stage II about one fifth of the patients developed a recurrence with one third of them having only local recurrence, and two thirds having either combined local and distant recurrence or distant recurrence alone. The small subgroup of pT4 pN0 had a very poor prognosis with early occurrence of distant metastases. In stage III the actuarial five-year survival was 25%, 60% of stage III cases had pN1 nodal disease. No patient with pN2-3 disease was alive after five years follow-up. The overall risk of distant metastases in stage III was 64%. Local recurrence rate was highly dependent on the pT-stage.(ABSTRACT TRUNCATED AT 250 WORDS)

Adenocarcinoma↗
PubMed2001

Abdominoperineal resection for locally recurrent rectal cancer.

To evaluate whether surgical resection confers survival advantages in selected patients with resectable locally recurrent rectal cancer, data on 430 patients who underwent R0 resection for primary rectal cancer were prospectively collected over a 14-year period. Resection of recurrent disease was considered R0 when all cancer tissue was resected with microscopically tumor-free surgical margins. Microscopic evidence of disease at resection margins was considered an R1 resection. Recurrent disease was detected in 158 of 430 patients. Local recurrence was found in 91 patients, including (79%) with resection-site relapse only. These patients were considered for surgery unless defined unresectability criteria were met. A total of 35 patients who had abdominoperineal excision following anterior resection were studied retrospectively. Mortality associated with the procedure was 3% and morbidity was 20%. The resection was R0 in 12 patients, while microscopic margins were involved in 23 patients. 10 patients had extended resection of one or several adjacent organs Median operating time and blood loss were 250 min and 500 ml respectively. Median hospital stay was 25 days. 21/23 R1 patients received postoperative radiotherapy. Return to normal activity occurred at 8.2 (SD 4.2) weeks. No patients were lost to follow-up. Overall median survival was 26.4 months; 5-year survival was 25.4%. In spite of several survival predictors at univariate analysis, R0 or R1 resection was the only independent predictor of survival at multivariate analysis (add ratio 112.7, 95% CI 3.6-3500, p=0.007). Median survival rate was not reached at the 146-month follow-up in patients with R0 resection. Median survival rate was 16.6 months in patients with R1 resection. In conclusion, uninvolved microscopic margins produce long-term survivors after surgical resection for locally recurrent rectal cancer.

Abdominal Muscles↗
PubMed2003

Incidence and prognostic value of positive peritoneal cytology in colorectal cancer.

PURPOSE: This study was conducted to investigate the incidence of free cancer cells in the peritoneal washings of patients who had undergone surgery for colorectal cancer and to evaluate its influence as a prognostic factor of the disease. METHODS: From 1990 to 1996, intraoperative washing cytology was performed in 110 patients who underwent surgery for colorectal cancer. All patients had curative resections. Immediately after the abdomen was opened and before exploration and mobilization of the tumor, 100 ml of saline was injected over the tumor site. Washings were then aspirated and taken for cytologic examination. RESULTS: Twenty-two (20 percent) of 110 patients examined were found to have positive cytology for intraperitoneal free malignant cells. The site of tumor in the colon or rectum, tumor size, nodal status, degree of differentiation, mucinous characteristics, and vascular or neural invasion were found not to affect the incidence of free cancer cells. Conversely, tumor penetration was found to affect the incidence of positive cytology. The degree of association among the stages of tumor penetration was indicated by the contingency coefficient, which was 0.42. Patients with positive cytology had a significantly higher rate of local recurrence and peritoneal carcinomatosis (22.8 vs. 8 percent, P = 0.05) than patients with negative cytology. Mortality rate was not found to be related to the presence of free cancer cells. CONCLUSION: Cytologic examination of peritoneal lavage at the time of surgery could be a useful prognostic indicator for local and peritoneal recurrence rate. However, it was not found to be a predictor of survival.

Adenocarcinoma↗